Cellceutix Chooses Destum Partners To Partner Psoriasis Compound

Cellceutix said that KM-133 is also an attractive compound as it may be eligible for an abridged FDA approval process that would allow the compound to go directly into human trials.

In a human xenograft animal model of psoriasis, KM-133 reduced psoriasis more than controls. Psoriasis did not recur with KM-133 during the entire 180 day course of the experiment, whereas psoriasis reoccurred in the groups treated with methotrexate, a drug commonly used for the treatment of severe psoriasis, after an average of 61 days.

George Evans, CEO of Cellceutix, said: “With our primary focus on the impending IND filing for Kevetrin and our work on KM-391 for autism, our board determined that this approach is the best way to increase value for our shareholders. We selected Destum because of their deep experience in the dermatology space and their excellent recent track record in concluding development deals.”

Gareth Lugg, managing director and co-founder of Destum Partners, said: “We are very pleased that Cellceutix selected us for this project. Although Cellceutix is a small company, the strength of their compounds in development is extraordinary.”